Want to see AU:DXB full AI Analyst Report?
Top Page
Dimerix Limited
(Sydney:DXB)
Select Model
Select Model
Rating:47Neutral
Price Target:
AU$0.29
▼(-1.38% Downside)
Action:Reiterated
Date:08/28/26
The score is held down primarily by weak financial performance (ongoing losses, negative/unstable cash flows, and negative equity in 2026). Technical indicators are somewhat constructive (positive MACD and price above key short/medium-term averages), but valuation is constrained by the lack of profitability and no dividend support.
Positive Factors
Low Debt Burden
Limited debt reduces interest and refinancing pressure, giving Dimerix greater flexibility to fund clinical programs. This is a durable balance-sheet advantage, although it does not offset the company’s need for external capital.
Negative Factors
Volatile and Declining Revenue
Unstable revenue indicates Dimerix has not established a durable commercial or partnership income stream. The 2026 decline weakens visibility into funding capacity and makes future results dependent on uncertain development or licensing milestones.
Read all positive and negative factors
Positive Factors
Negative Factors
Low Debt Burden
Limited debt reduces interest and refinancing pressure, giving Dimerix greater flexibility to fund clinical programs. This is a durable balance-sheet advantage, although it does not offset the company’s need for external capital.
Read all positive factors
Dimerix Limited (DXB) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$171.11M
Dividend YieldN/A
Average Volume (3M)1.20M
Price to Earnings (P/E)―
Beta (1Y)2.57
Revenue Growth-22.13%
EPS Growth-108.82%
CountryAU
Employees15
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)N/A
Shares Outstanding600,396,800
10 Day Avg. Volume730,334
30 Day Avg. Volume1,196,159
Financial Highlights & Ratios
PEG Ratio-0.04
Price to Book (P/B)-8.34
Price to Sales (P/S)28.29
P/FCF Ratio-2.38
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Dimerix Limited Business Overview & Revenue Model
Company Description
Dimerix Limited is an Australian biopharmaceutical firm dedicated to discovering and bringing to market innovative pharmaceutical solutions for medical conditions where existing treatments are insufficient. The company's leading therapeutic candid...
How the Company Makes Money
Dimerix primarily seeks to generate income through the development and out-licensing/commercial partnering of its drug candidates rather than through established product sales. The company’s potential revenue model is typically biopharma-based and...
Dimerix Limited Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
30
Negative
Cash Flow
22
Negative
| Breakdown | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 4.35M | 1.25M | 583.48K | 36.79K | 6.46M |
| Gross Profit | 4.21M | 1.25M | 583.48K | 36.79K | 6.41M |
| EBITDA | -37.04M | -36.22M | -24.96M | -22.68M | -16.47M |
| Net Income | -29.81M | -13.25M | -17.07M | -13.80M | -10.49M |
Balance Sheet | |||||
| Total Assets | 58.59M | 91.18M | 32.08M | 17.76M | 16.50M |
| Cash, Cash Equivalents and Short-Term Investments | 16.15M | 68.28M | 22.14M | 7.99M | 9.63M |
| Total Debt | 232.09K | 97.48K | 149.68K | 5.96M | 73.10K |
| Total Liabilities | 73.35M | 77.80M | 13.89M | 11.79M | 2.07M |
| Stockholders Equity | -14.76M | 13.38M | 18.19M | 5.96M | 14.42M |
Cash Flow | |||||
| Free Cash Flow | -51.81M | 39.03M | -7.02M | -12.73M | -13.45M |
| Operating Cash Flow | -51.81M | 39.05M | -7.00M | -12.73M | -13.44M |
| Investing Cash Flow | -4.98K | -21.01K | -15.80K | -2.30K | -10.61K |
| Financing Cash Flow | 118.47K | 7.42M | 21.17M | 11.07M | 17.69M |
Dimerix Limited Technical Analysis
Negative
0.29
Price Trends
0.27
Positive
0.24
Positive
0.36
Negative
Market Momentum
<0.01
Positive
48.12
Neutral
44.59
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:DXB, the sentiment is Negative. The current price of 0.29 is below the 20-day moving average (MA) of 0.29, above the 50-day MA of 0.27, and below the 200-day MA of 0.36, indicating a neutral trend. The MACD of <0.01 indicates Positive momentum. The RSI at 48.12 is Neutral, neither overbought nor oversold. The STOCH value of 44.59 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:DXB.
Dimerix Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | AU$198.79M | -11.04 | -103.42% | ― | ― | 5.88% | |
47 Neutral | AU$171.11M | -5.73 | 362.74% | ― | -22.13% | -108.82% | |
47 Neutral | AU$57.47M | -0.65 | -118.74% | ― | 499.47% | 31.20% | |
43 Neutral | AU$113.13M | -7.14 | 84.67% | ― | ― | 42.51% | |
42 Neutral | AU$70.74M | -0.89 | -98.86% | ― | ― | -27.73% | |
41 Neutral | AU$110.35M | -4.53 | -48.25% | ― | ― | -16.21% |
* Healthcare Sector Average
AU:DXB
Dimerix Limited
0.29
-0.23
-44.12%
AU:ACW
Actinogen Medical
0.05
0.03
96.30%
AU:ATH
Alterity Therapeutics
0.50
-0.15
-23.08%
AU:IMM
Immutep Ltd
0.05
-0.20
-80.41%
AU:BOT
Botanix Pharmaceuticals Limited
0.02
-0.12
-85.00%
AU:RCE
Recce Pharmaceuticals Ltd.
0.37
-0.08
-17.78%
Dimerix Limited Corporate Events
Dimerix Files 2026 Corporate Governance Disclosures with ASX
Aug 26, 2026
Dimerix Limited has lodged its Appendix 4G and confirmed the location of its corporate governance statement for the financial year ended 30 June 2026, in line with ASX Listing Rules. The statement, approved by the board, outlines how the company f...
Dimerix lifts revenue but annual loss more than doubles
Aug 26, 2026
Dimerix Limited is a publicly listed biopharmaceutical company focused on developing and commercialising therapies, with activities centred on research, clinical development and related operations. The group generates revenue from ordinary activit...
Dimerix Secures US$10m Everest Payment as DMX-200 Global Strategy Advances
Aug 20, 2026
Dimerix Limited, a clinical-stage biopharmaceutical company headquartered in Melbourne, is developing DMX-200 for the treatment of rare kidney diseases, most notably focal segmental glomerulosclerosis. The company is pursuing global market access ...
Dimerix Takes Control of U.S. IND for New Renal Asset DMX-652
Aug 16, 2026
Dimerix Limited, a Melbourne-based clinical-stage biopharmaceutical company, is building a portfolio of kidney disease treatments, led by its Phase 3 candidate DMX-200 for focal segmental glomerulosclerosis. The company is also progressing a Phase...
Dimerix highlights kidney disease pipeline and diversification strategy at Bioshares Summit
Aug 5, 2026
Dimerix Limited, a clinical-stage biopharmaceutical group, is building a specialised portfolio of kidney disease therapies centred on its lead candidate DMX-200 for focal segmental glomerulosclerosis. The company is also advancing DMX-652 for acut...
Dimerix to Highlight Kidney Disease Pipeline Progress at TechKnow Invest Conference
Jul 26, 2026
Dimerix Limited will showcase its progress in kidney disease therapeutics at the TechKnow Invest Conference in Melbourne and Sydney from 27 to 29 July 2026, with CEO Dr Nina Webster and COO Dr Robert Shepherd presenting. The company will provide u...
Dimerix Secures Long-Term U.S. Patent Protection for Phase 2 Kidney Drug DMX-652
Jul 22, 2026
Dimerix Limited has secured a U.S. composition of matter patent for its newly acquired Phase 2-ready asset DMX-652, a first and best-in-class USP30 inhibitor designed to prevent kidney injury and promote mitophagy. The patent, which now runs until...
Dimerix Strikes Major Asian Licensing Deal for Phase 3 Kidney Drug DMX-200
Jun 16, 2026
Dimerix has signed an exclusive licensing agreement granting Everest Medicines rights to commercialise its Phase 3 kidney drug candidate DMX-200 for all indications, including focal segmental glomerulosclerosis, across Greater China, South Korea a...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.